Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study...